In the 2001 trial, patients experienced an average of 1.4 mm growth in length (a 25% increase) and a 106 percent increase in fullness and thickness at week 16.
The study's findings led to Latisse® being the first and only FDA-approved medication for patients with inadequate lashes to lengthen, darken, and thicken their lashes.